|
| Trials | Agents Used | Additional Details | Organization |
|
| Phase I |
|
| Study of Sorafenib and Bevacizumab in patients with refractory, metastatic, or unresectable solid tumors | Sorafenib plus Bevacizumab
| Determine biochemical changes in the Ras-Raf-MAPK, and VEGF signal transduction pathways in tumor and stromal cells from patients treated with this regimen. | NCI—Center for Cancer Research (NCT00098592) |
|
| IMC-A12 in combination with Temsirolimus (CCI-779) in patients with advanced cancers | combination of IMC-A12 and Temsirolimus | Researchers will also perform biomarker tests to study how IMC-A12 and Temsirolimus affect genes | MD Anderson Cancer Center (NCT00678769) |
|
| Phase II |
|
| Study of combination comprising Tariquidar, Mitotane, Doxorubicin, Vincristine, and Etoposide and surgery in patients with recurrent, metastatic, or primary unresectable adrenocortical cancer | Tariquidar, Mitotane, Doxorubicin, Vincristine, and Etoposide | Primary outcome: response rate (partial or complete)progression-free survival
| NCI—Center for Cancer Research (NCT00073996) |
|
Trial with Taxotere and Cisplatin in nonoperable adrenocortical carcinoma
| Cisplatin plus Taxotere | The primary objective: to investigate response rate. Secondary endpoints are survival, time to progression, best overall response rate, and duration of response. | Rigshospitalet-Copenhagen University Hospital (NCT00324012)
|
|
| Randomized study of Mitotane with versus without anti-IGF-1R recombinant monoclonal antibody IMC-A12 in patients with recurrent, metastatic, or primary unresectable adrenocortical carcinoma | Mitotane with IMC-A12 versus Mitotane without IMC-A12 | Primary outcome: progression-free survival, objective response rates, changes in tumor size over time, and overall survival
| University of Chicago Cancer Research Center (NCT00778817) |
|
| Study of Cixutumumab in patients with relapsed or refractory solid tumors | Cixutumumab | Primary outcome: response rate toxicity | Children's Oncology Group (NCT00831844) |
|
| Study of R-(-)-gossypol acetic acid in patients with recurrent, metastatic, or primary unresectable adrenocortical carcinoma | R-(-)-gossypol acetic acid. | Proportion of patients who achieve a confirmed objective response (complete or partial response by RECIST criteria) to treatment | Mayo Clinic Cancer Center (NCT00848016) |
|
| Study of axitinib (AG-013736) with evaluation of the VEGF-pathway in metastatic, recurrent or primary unresectable adrenocortical cancer | Axitinib (AG-013736) | Determine the response rate of Axitinib (AG-013736) in recurrent, metastatic, or primary unresectable ACC
| National Cancer Institute (NCT01255137) |
|
| Sorafenib plus Paclitaxel in adreno-cortical-cancer patients | Sorafenib plus weekly Paclitaxel | Primary outcome: progression-free survival rate ≥ 40% after 4 months. Response rate evaluation. | University of Turin, Italy (NCT00786110) |
|
| Phase III |
|
| GALACCTIC: a study of OSI-906 in patients with locally advanced or metastatic adrenocortical carcinoma | OSI-906
| A multicenter, randomized, double-blind, and placebo-controlled phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic ACC who received at least one but no more than two prior drug regimen | OSI Pharmaceuticals Incorporated (NCT00924989) |
|
| Study of neoadjuvant and adjuvant Cisplatin-based chemotherapy and/or surgical resection in young patients with stage I–IV adrenocortical tumor | Oral mitotane; cisplatin IV; Etoposide IV and doxorubicin hydrochloride IV | | Children's Oncology Group (NCT00304070) |
|
